TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06056492

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Experience of nitrous oxide sedation at assessment
Description: Apart from the Lead researcher, a dental nurse assisted with the dental treatment on every appointment. A specially trained sedation nurse was responsible for the monitoring during sedation. The Porter Brown inhalation sedation machine (RA Services, Keighly, W. Yorkshire, UK) was used. Once the appropriate nasal hood was selected, 100% O2 was introduced for 1-2 minutes. Following that, the level of N2O was increased in 10% increments until signs of sedation were observed. The endpoint was between 30-40% nitrous oxide.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experience of nitrous oxide sedation at assessment
Description: Apart from the Lead researcher, a dental nurse assisted with the dental treatment on every appointment. A specially trained sedation nurse was responsible for the monitoring during sedation. The Porter Brown inhalation sedation machine (RA Services, Keighly, W. Yorkshire, UK) was used. Once the appropriate nasal hood was selected, 100% O2 was introduced for 1-2 minutes. Following that, the level of N2O was increased in 10% increments until signs of sedation were observed. The endpoint was between 30-40% nitrous oxide.
Study: NCT00068341

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Cycle 5-7 post-op only Day 1 4mg/kg IV Day 8, 15 2mg/kg IV Cycle 8 Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Cycle 1-8 Day 1 or 2 AUC = 6 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Cycle 1-8 Day 1 or 2 AUC = 6 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Cycle 1-8 Day 1 or 2 AUC = 6 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Cycle 1-8 Day 1 or 2: 75 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Cycle 1-8 Day 1 or 2: 75 mg/m2 IV
Study: NCT03530683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maplirpacept (PF-07901801)
Description: maplirpacept (PF-07901801) will be administered by intravenous infusion at ranging doses, as determined from sequential dosing cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: intravenous (IV) or subcutaneous (SC) daily for 7 days, repeated every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: intravenous (IV) or subcutaneous (SC) daily for 7 days, repeated every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: orally daily for each day of each cycle (first 7 doses taken in clinic). The ramp-up and target dose of venetoclax will be adjusted per the package insert in subjects who are taking concomitant moderate or strong CYP3A4 inhibitors or posaconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Days 1, 8, and 15 of 28-day cycles; starting dose IV given on Cycle (C) 1 Day (D) 1, and if tolerated, then increased dose via IV given starting on C1D8 and subsequent doses thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Days 1, 8, and 15 of 28-day cycles; starting dose IV given on Cycle (C) 1 Day (D) 1, and if tolerated, then increased dose via IV given starting on C1D8 and subsequent doses thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: starting dose via IV on Days 1, 8, 15, and increased dose via IV on 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: starting dose via IV on Days 1, 8, 15, and increased dose via IV on 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD20 Targeting agent
Description: Days 1,8,15, and 22 of the first 28-day cycle and then on Day 1 of subsequent 21-day cycles. The anti-CD20 targeting agent will be administered for a total of eight doses, and then Cohort F1, F2 and F3: TTI-622 + isatuximab, carfilzomib and dexamethasone Cohort C1, C2 and C3: TTI-622 + Carfilzomib and Dexamethasone will be continued as single-agent therapy.
Study: NCT00068341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Cycle 1-8 Day 1 or 2: 75 mg/m2 IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Cycle 1-4 pre-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV~Cycle 5-7 post-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV~Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV
Study: NCT02857673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Abuse Prevention Problem Solving
Description: The CAPPS intervention includes problem solving, motivational interviewing, and referral to existing services. Intervention providers will conduct three core problem solving sessions and three sessions tailored to the common problems experienced by parents of CSHCN: caregiver burden, difficulties navigating complex medical services, and social isolation. Intervention providers will use their motivational interviewing skills during regular, ongoing interactions with their clients to enhance willingness to participate meaningfully in CAPPS sessions. Referral to existing services in the medical home and in the community will occur as needs arise during CAPPS sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Group
Description: Parents in both study groups will receive the standard medical and social work services offered in the patient-centered medical homes where their children receive care. In addition, to account for potential surveillance bias, families in the control group will be contacted by a member of the study team six times over 12 weeks, approximating the frequency of contact that the intervention group receives from the CAPPS providers.
Study: NCT01493401

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Midurethral slings (MUS)
Description: Retropubic, Transobturator, and Single incision MUS can be used.
Study: NCT04050618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fanfilcon A test lens
Description: Silicone hydrogel contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fanfilcon A test lens
Description: Silicone hydrogel contact lens
Study: NCT02209272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bacteriostatic saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buffered lidocaine
Study: NCT03545568

Intervention type: OTHER
Group type: OTHER
Intervention: Neu5Ac supplementation
Description: Sialic acid as N-Acetyl-neuraminic acid dehydrate (Neu5Ac) 150 mg/kg/d (max 12g/d) in three doses orally in subjects with NANS deficiency compared to controls
Study: NCT02476058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
Study: NCT03882567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electro Neuro adaptative Regulator
Description: The SCENAR device has been previously described and generates high-amplitude, pulsed, damped biphasic sinusoidal current that is delivered to the tissue via a pair of concentric electrodes placed in direct contact with the target area. The intensity of the interactive waveform adjusts in response to changes in skin impedance

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Electro Neuro adaptative Regulator
Description: The SCENAR device has been previously described and generates high-amplitude, pulsed, damped biphasic sinusoidal current that is delivered to the tissue via a pair of concentric electrodes placed in direct contact with the target area. The intensity of the interactive waveform adjusts in response to changes in skin impedance
Study: NCT04209166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)
Description: Patients will be treated with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)
Description: Patients will be treated with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
Study: NCT03530683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: F1: IV dose C0D1, C0D8, C0D15 and C0D22 (lead in phase);weekly during Cycle 1; Cycle 2 and beyond will be administered on Days 1 and 15 (Q2W).~F2 and F3: IV dose C0D1 and C0D8 (lead in phase); C1D1, C1D8, C1D15 and C1D22; Cycle 2 and beyond will be administered on days 1 and 15 (Q2W). Carfilzomib: IV dose on days 1 and 2 of cycle 1; then increased IV dose on days 8, 9, 15, and 16 of cycle 1; cycle 2 and beyond: increased IV dose on days 1, 2, 8, 9, 15, and 16. Dexamethasone IV or PO on days 1, 2, 8, 9, 15, 16, 22, and 23 starting cycle 1.
Study: NCT04328090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer based Antimicrobial stewardship (AMS) intervention system
Description: 1. Re-evaluation alerts and decision support for the duration of antimicrobial treatment.~2. Re-evaluation alerts and decision support for the choice of antimicrobial.~3. Quality control audit and feedback.
Study: NCT04209166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs/SNRIs+Mood Stabilizer
Description: Patients will be treated with Mood Stabilizer combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
Study: NCT04050618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ocufilcon D control lens
Description: hydrogel contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A control lens
Description: hydrogel contact lens
Study: NCT00097448

Intervention type: DRUG
Group type: OTHER
Intervention: prednisone
Description: Oral, 19 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone sodium succinate
Description: Four intratympanic injections delivered to the middle ear over 2 weeks
Study: NCT02292693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: Direct laryngoscopy. Laryngoscopy with Miller blade
Study: NCT04209166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs/SNRIs+Quetiapine
Description: Patients will be treated with Quetiapine combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs/SNRIs+Quetiapine
Description: Patients will be treated with Quetiapine combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Usual Treatment
Description: Patients' treatment will be decided by the clinical doctor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Usual Treatment
Description: Patients' treatment will be decided by the clinical doctor.
Study: NCT02466191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Study: NCT00655226

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis C educational support groups
Description: Hepatitis C educational support groups

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy skills based group sessions
Description: Eight CBT group sessions tailored for hepatitis C patients conducted by a clinical psychologist: 3 sessions conducted prior to IFN/ribavirin initiation, 1 session the day of IFN/ribavirin initiation, and 4 sessions during IFN/ribavirin treatment.
Study: NCT02250157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oratecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oratecan
Study: NCT02120456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03199924

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Intramuscular injection of 75mg / 3ml of Diclofenac solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Intramuscular injection of 75mg / 3ml of Diclofenac solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Intramuscular injection of 75mg / 3ml of Diclofenac solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: intravenous injection of 1 g magnesium solution diluted in 10ml of saline solution administered over 2 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: intravenous injection of 10ml lidocaine 1% solution administered over 2 minutes
Study: NCT03449277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Tablet
Description: oral labetalol tablets and oral nifedipine tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Tablet
Description: oral labetalol tablets and oral nifedipine tablets
Study: NCT02098707

Intervention type: OTHER
Intervention: Stabilometric Platform
Description: Stabilometric platform is a device used for assessment and training of balance basing on ground reaction force evaluation in static conditions.
Study: NCT03583840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ScreenMen website
Description: An educational website that aims to improve evidence-based health screening uptake in men
Study: NCT03205046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib
Description: Acalabrutinib is a selective, irreversible small molecule Bruton's tyrosine kinase (BTK) inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib
Description: Acalabrutinib is a selective, irreversible small molecule Bruton's tyrosine kinase (BTK) inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vistusertib
Description: Vistusertib is an inhibitor of mechanistic target of rapamycin (mTOR) kinase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vistusertib
Description: Vistusertib is an inhibitor of mechanistic target of rapamycin (mTOR) kinase
Study: NCT04441437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-oriented training with a dynamic hand splint
Description: In addition to conventional rehabilitation programs (therapy-as-usual), the subject in the splint group received 1-hour task-oriented training with wearing a customized dynamic hand splint, totally 15 times in a duration of one month. The content of task-oriented training contained picking cubes from side to side with three-jaw grasp, lifting the cone to the shoulder height with the cylindrical grip and an extended elbow, picking up pegs and inserting it into the hole with palmar pinch, and grasping a soap to simulate wiping the body. Among the four tasks, two were chosen to train the subjects according to the abilities of subjects.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Task-oriented training without a dynamic hand splint
Description: In addition to conventional rehabilitation programs (therapy-as-usual), the subject in the no-splint group received 1-hour task-oriented training, totally 15 times in a duration of one month. The content of task-oriented training contained picking cubes from side to side with three-jaw grasp, lifting the cone to the shoulder height with the cylindrical grip and an extended elbow, picking up pegs and inserting it into the hole with palmar pinch, and grasping a soap to simulate wiping the body. Among the four tasks, two were chosen to train the subjects according to the abilities of subjects.
Study: NCT01459588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose Based Eye Drop Formulation A
Description: Carboxymethylcellulose Based Eye Drop Formulation A (Refresh Optive® Advanced Sensitive Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose Based Eye Drop Formulation B
Description: Carboxymethylcellulose Based Eye Drop Formulation B (Refresh Optive® Advanced Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops
Description: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (Optive® Sensitive Preservative-Free Lubricant Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
Study: NCT00138801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Study: NCT01459588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboxymethylcellulose Based Lubricant Eye Drops
Description: Carboxymethylcellulose Based Lubricant Eye Drops (Optive® Lubricant Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
Study: NCT01362608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab, ACZ885
Description: Canakinumab and placebo matching to triamcinolone acetonide
Study: NCT00138801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Study: NCT02292693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAC
Description: Direct laryngoscopy. Laryngoscopy with Macintosh blade
Study: NCT01362608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Description: Triamcinolone acetonide 40 mg and placebo matching to canakinumab
Study: NCT02734745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flash glucose monitoring
Description: Patients will use Freestyle Libre for 14 days at home, during this period they will have to perform at least 7 measurements of capillary blood glucose per day . Patients also will go to our clinical center on two separate occasions , to run a test breakfast. In one of the two occasions it will be specifically induced a moderate initial hyperglycemia and subsequent hypoglycemia . During the test meal and in the subsequent hours for a total of 6 hours , will be carried out frequent blood sampling for measurement of blood glucose using the Yellow Springs glucose analyzer ( YSI system ) , simultaneous measurements with Freestyle Libre and with glucometer.
Study: NCT02292693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McCoy
Description: Direct laryngoscopy. Laryngoscopy with McCoy blade
Study: NCT02152306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan and Amlodipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Study: NCT03194126

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mifepristone + Misoprostol OR oxytocine + laminaria
Description: Three laminaria placed 12 hours prior to administration of misoprostol

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mifepristone + Misoprostol OR oxytocine
Description: standart support
Study: NCT03777059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Atogepant tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Atogepant tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Atogepant tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching atogepant tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching atogepant tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching atogepant tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching atogepant tablets
Study: NCT04915443

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Periotome
Description: Dental instrument used to perform atraumatic dental extraction.~After the initial de attachment, the periotome was inserted between the root and the bone parallel to the long axis of the root and pushed apically to the maximum depth that the tissue allowes severing the PDL and leaving it for 10-15 seconds allowing the biomechanical creep to occur.~This proses is repeated at different points of entries at all the different surfaces of the tooth.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piezotome
Description: Dental device used for many purposes one of which is performing atraumatic dental extraction.~An LC2 tip was used for all the procedures and it was inserted between the tooth root and the bone parallel to the long axis of the root and moved in a sweeping motion 3-4mm toward the apex severing the PDL.
Study: NCT02403999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test shampoo
Description: Participants used Oilatum Soothe \& Protect Shampoo at home in place of their usual wash product at least twice weekly for a two week period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test bath foam
Description: Participants used Oilatum Soothe \& Protect Bath Foam at home in place of their usual wash product at least twice weekly for a two week period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test head to toe wash
Description: Participants used Oilatum Soothe \& Protect Head to Toe Wash at home in place of their usual wash product at least twice weekly for a two week period.
Study: NCT01841723

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT02884089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iohexol
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT06161792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.8 mg RCN3028
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral